Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9998878 | 0.88 | ACACB (0.42) | ACACBSYKL3MBTL1GPR119KDM4E | |
| SCHEMBL15167524 | 0.87 | ACACB (0.40) | ACACBSYKL3MBTL1GPR119NAMPT | |
| SCHEMBL3249336 | 0.81 | POLB (0.52) | SYKGPR119NAMPT | |
| SCHEMBL4282943 | 0.80 | CCR1 (0.42) | ACACBSYKGPR119NAMPT | |
| SCHEMBL30136853 | 0.79 | L3MBTL1 (0.44) | ACACBSYKL3MBTL1GPR119KDM4E | |
| SCHEMBL16836091 | 0.79 | L3MBTL1 (0.44) | ACACBSYKL3MBTL1GPR119KDM4E | |
| SCHEMBL29335912 | 0.79 | GPR119 (0.41) | ACACBSYKGPR119NAMPT | |
| SCHEMBL31046207 | 0.79 | GPR119 (0.41) | ACACBSYKGPR119NAMPT | |
| SCHEMBL12074307 | 0.78 | GPR119 (0.41) | ACACBSYKGPR119NAMPT | |
| SCHEMBL9998899 | 0.78 | GPR119 (0.41) | ACACBSYKGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | ACACB 3659/4885SYK 552/4885L3MBTL1 4698/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | ACACB 3782/4885SYK 469/4885L3MBTL1 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.